Ardelyx, Inc. (ARDX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.08-3.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Ardelyx, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-2.6%

+10% or more+5%0%−5%−10% or less

0.26 → 0.25 EPS · FY ending Dec 31, 2027 · 8 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 8 to 8; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	143.14M
EPS	—	0.048
FY 2026 · Annual
Revenue	—	487.14M
EPS	—	-0.179
Operating expenses	$500M	—
FY 2027 · Annual
Revenue	—	624.05M
EPS	—	0.253

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage debt and funding without excessive dilution	A supporting condition in Ardelyx, Inc.'s published investment case. The stated target is No further large debt raises beyond current $50M loan.	Intact	New large debt or equity raises that dilute shareholders or increase leverage materially	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Move toward profitability with positive EPS by 2027	A supporting condition in Ardelyx, Inc.'s published investment case. The stated target is EPS >= $0.50.	Improving	EPS remains negative or below $0.50 in FY27	Diluted EPS: $-0.07 per share FY2026-Q2; GAAP. Published target: EPS >= $0.50. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.07 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 933c2dc6-f0e6-4f12-8118-ee5e252eb4e2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Total revenue reaches $270-275M in 2025	A primary condition in Ardelyx, Inc.'s published investment case. The stated target is >= $270 million.	Intact	total revenue falls below $270 million in FY25	Revenue: $120.877M FY2026-Q2; GAAP. Published target: >= $270 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026120,877,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 933c2dc6-f0e6-4f12-8118-ee5e252eb4e2. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. XPHOZAH revenue increased from $23.3 million in 2026-Q1 to $31.9 million in 2026-Q2, supporting the reiterated full-year guidance of $110-$120 million. The trajectory is delivering consistent growth. Delivery assessment Oct 24, 2026
XPHOZAH revenue reaches $110-120M in 2026	A primary condition in Ardelyx, Inc.'s published investment case. The stated target is >= $110 million.	Intact	XPHOZAH revenue falls below $110 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. XPHOZAH revenue increased from $23.3 million in 2026-Q1 to $31.9 million in 2026-Q2, supporting the reiterated full-year guidance of $110-$120 million. The trajectory is delivering consistent growth. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.25

$0.52 → $0.25 · observed estimates

FY2027 revenue$0.62B

$0.74B → $0.62B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.52	$739,579,020	7 / 11
2026-07-25	$0.52	$739,579,020	7 / 11
2026-07-26	$0.52	$739,579,020	7 / 11
2026-07-27	$0.48	$739,553,570	8 / 8
2026-07-28	$0.52	$739,579,020	7 / 11
2026-07-29	$0.52	$739,579,020	7 / 11
2026-07-30	$0.52	$739,579,020	7 / 11
2026-07-31	$0.52	$739,579,020	7 / 11
2026-08-01	$0.52	$739,579,020	7 / 11
2026-08-02	$0.52	$739,579,020	7 / 11
2026-08-03	$0.52	$739,579,020	7 / 11
2026-08-04	$0.52	$739,579,020	7 / 11
2026-08-05	$0.52	$739,579,020	7 / 11
2026-08-06	$0.52	$739,579,020	7 / 11
2026-08-07	$0.47	$738,735,416	8 / 8
2026-08-08	$0.52	$716,615,390	7 / 11
2026-08-09	$0.52	$716,615,390	7 / 11
2026-08-10	$0.52	$716,615,390	7 / 11
2026-08-11	$0.32	$643,697,980	7 / 11
2026-08-12	$0.32	$643,697,980	7 / 11
2026-08-13	$0.32	$638,363,250	7 / 11
2026-08-14	$0.47	$738,735,416	8 / 8
2026-08-15	$0.47	$738,735,416	8 / 8
2026-08-16	$0.47	$738,735,416	8 / 8
2026-08-17	$0.47	$738,735,416	8 / 8
2026-08-18	$0.47	$738,735,416	8 / 8
2026-08-19	$0.47	$738,735,416	8 / 8
2026-08-20	$0.47	$738,735,416	8 / 8
2026-08-21	$0.26	$623,895,217	8 / 8
2026-08-22	$0.26	$623,895,217	8 / 8
2026-08-23	$0.26	$623,895,217	8 / 8
2026-08-24	$0.26	$623,895,217	8 / 8
2026-08-25	$0.26	$623,895,217	8 / 8
2026-08-26	$0.26	$623,895,217	8 / 8
2026-08-27	$0.26	$623,895,217	8 / 8
2026-08-28	$0.26	$623,895,217	8 / 8
2026-08-29	$0.26	$623,895,217	8 / 8
2026-08-30	$0.26	$623,895,217	8 / 8
2026-08-31	$0.26	$623,895,217	8 / 8
2026-09-01	$0.26	$623,895,217	8 / 8
2026-09-02	$0.26	$623,895,217	8 / 8
2026-09-03	$0.26	$623,895,217	8 / 8
2026-09-04	$0.26	$623,895,217	8 / 8
2026-09-05	$0.26	$623,895,217	8 / 8
2026-09-06	$0.26	$623,895,217	8 / 8
2026-09-07	$0.26	$623,895,217	8 / 8
2026-09-08	$0.26	$623,895,217	8 / 8
2026-09-09	$0.26	$623,895,217	8 / 8
2026-09-10	$0.26	$623,895,217	8 / 8
2026-09-11	$0.26	$623,895,244	8 / 8
2026-09-12	$0.26	$623,895,244	8 / 8
2026-09-13	$0.26	$623,895,244	8 / 8
2026-09-14	$0.26	$623,895,244	8 / 8
2026-09-15	$0.26	$623,895,244	8 / 8
2026-09-16	$0.26	$623,895,244	8 / 8
2026-09-17	$0.26	$623,895,244	8 / 8
2026-09-18	$0.26	$623,895,244	8 / 8
2026-09-19	$0.26	$623,895,244	8 / 8
2026-09-20	$0.26	$623,895,244	8 / 8
2026-09-21	$0.26	$623,895,244	8 / 8
2026-09-22	$0.26	$623,895,244	8 / 8
2026-09-23	$0.26	$623,895,244	8 / 8
2026-09-24	$0.26	$623,895,244	8 / 8
2026-09-25	$0.26	$623,895,244	8 / 8
2026-09-26	$0.26	$623,895,244	8 / 8
2026-09-27	$0.26	$623,895,244	8 / 8
2026-09-28	$0.26	$623,895,244	8 / 8
2026-09-29	$0.26	$623,895,244	8 / 8
2026-09-30	$0.26	$623,895,244	8 / 8
2026-10-01	$0.26	$623,895,244	8 / 8
2026-10-02	$0.26	$623,895,244	8 / 8
2026-10-03	$0.26	$623,895,244	8 / 8
2026-10-04	$0.26	$623,895,244	8 / 8
2026-10-05	$0.26	$623,895,244	8 / 8
2026-10-06	$0.25	$624,077,062	8 / 8
2026-10-07	$0.25	$624,077,062	8 / 8
2026-10-08	$0.25	$624,077,062	8 / 8
2026-10-09	$0.25	$624,077,062	8 / 8
2026-10-10	$0.25	$624,077,062	8 / 8
2026-10-11	$0.25	$624,077,062	8 / 8
2026-10-12	$0.25	$624,077,062	8 / 8
2026-10-13	$0.25	$624,077,062	8 / 8
2026-10-14	$0.25	$624,077,062	8 / 8
2026-10-15	$0.25	$624,077,062	8 / 8
2026-10-16	$0.25	$624,077,062	8 / 8
2026-10-17	$0.25	$624,077,062	8 / 8
2026-10-18	$0.25	$624,077,062	8 / 8
2026-10-19	$0.25	$624,077,062	8 / 8
2026-10-20	$0.25	$624,077,062	8 / 8
2026-10-21	$0.25	$624,048,280	8 / 8
2026-10-22	$0.25	$624,048,280	8 / 8
2026-10-23	$0.25	$624,048,280	8 / 8
2026-10-24	$0.25	$624,048,280	8 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	11	0	0
2026-07-01	11	0	0
2026-08-01	11	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage debt and funding without excessive dilutionDirect metric needs a verified mapping
Move toward profitability with positive EPS by 2027Diluted EPS: $-0.07 per share
Total revenue reaches $270-275M in 2025Revenue: $120.877M
XPHOZAH revenue reaches $110-120M in 2026Direct metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-61.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Ardelyx, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk growth story, not a proven compounder, because earnings remain loss-making. The long-term thesis is on watch: product revenue goals are progressing, but recent performance has lagged its industry cohort.

What's priced into Ardelyx, Inc.

ARDX screens as cheap versus peers, but confidence in that comparison is low. The expectations gap is negative, and the priced-in assessment is tagged as justified, with no fragility warning; this suggests the valuation does not clearly signal that expectations are unusually stretched.

What the fundamentals likely do

Near term, IBSRELA and XPHOZAH revenue growth supports management’s 2026 goals, and ACCEL trial enrollment remains on track for completion by year-end, with data expected in the second half of 2027. The main near-term concern is execution: ARDX has a run of earnings misses, and the next print carries elevated miss risk.

What Ardelyx, Inc. hinges on

A guidance increase next quarter after the August reduction would support a recovery in execution, while further weakness would deepen concerns. Over the multi-year view, delivery on product revenue goals and progress toward ACCEL data are key; broader Healthcare sector momentum is a supporting factor, but the evidence for its effect on ARDX is limited.